Regarding tumor related factors, functioning (growth hormone producing tumors: 71%, prolactinomas 63–75%) and non-functioning pituitary tumors (43–100%) seem to have similar visual outcomes with regard to visual field deficits and unspecified visual improvement [8, 10, 19, 28, 31, 32, 37, 42, 44, 46]. The gene discussed is GH1; the disease is neoplasm.